anselcacabtagene autoleucel

anselcacabtagene autoleucel is described in secondary pipeline references as an investigational, genetically modified autologous chimeric antigen receptor (CAR) T‑cell therapy, but no primary regulatory, clinical trial registry, or major database entries specific to this construct can be identified. Based on its naming convention, it is expected to be a patient‑specific cell therapy in which autologous T cells are collected, engineered ex vivo to express a tumor‑targeting CAR, expanded, and reinfused, but its precise target, construct design, development sponsor, and lead indications have not been reliably characterized in public sources.